The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

Andrew W. Hahn; Deepika Sirohi; Neeraj Agarwal

doi:10.1016/j.euf.2019.03.003

The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

Andrew W. Hahn, Deepika Sirohi, Neeraj Agarwal

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Abstract

In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.

Original language	English (US)
Pages (from-to)	11-13
Number of pages	3
Journal	European Urology Focus
Volume	6
Issue number	1
DOIs	https://doi.org/10.1016/j.euf.2019.03.003
State	Published - Jan 15 2020
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2019.03.003

Cite this

@article{7a2b9efa72a344c795b4645b05f14c0d,

title = "The Role of PD-L1 Testing in Advanced Genitourinary Malignancies",

abstract = "In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.",

author = "Hahn, {Andrew W.} and Deepika Sirohi and Neeraj Agarwal",

note = "Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = jan,

day = "15",

doi = "10.1016/j.euf.2019.03.003",

language = "English (US)",

volume = "6",

pages = "11--13",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

AU - Hahn, Andrew W.

AU - Sirohi, Deepika

AU - Agarwal, Neeraj

PY - 2020/1/15

Y1 - 2020/1/15

N2 - In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.

AB - In accordance with US Food and Drug Administration recommendations, tumor PD-L1 expression should be assessed in all patients with platinum-ineligible metastatic urothelial carcinoma (mUC), and patients with low PD-L1 expression should not receive single-agent immune checkpoint inhibition treatment. By contrast, PD-L1 should not be tested in metastatic renal cell carcinoma and platinum-refractory mUC.

UR - http://www.scopus.com/inward/record.url?scp=85062597437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062597437&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.03.003

DO - 10.1016/j.euf.2019.03.003

M3 - Comment/debate

C2 - 30872123

AN - SCOPUS:85062597437

SN - 2405-4569

VL - 6

SP - 11

EP - 13

JO - European Urology Focus

JF - European Urology Focus

IS - 1

ER -

The Role of PD-L1 Testing in Advanced Genitourinary Malignancies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this